Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| Weiss Ratings | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 826.09 | |||
| Price History | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | -90.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -99.78% | |||
| 2-Year Total Return | -99.97% | |||
| 3-Year Total Return | -99.99% | |||
| 5-Year Total Return | -99.99% | |||
| 52-Week High % Change | -99.92% | |||
| 52-Week Low % Change | 9,900.00% | |||
| Price | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.13 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | May 23, 2024 | |||
| 52-Week High Price (Date) | Sep 30, 2024 | |||
| Valuation | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.00K | |||
| Enterprise Value | -2.30M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.05 | |||
| Earnings Per Share Growth | -90.40% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -3,837.55 | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | 0.23 | |||
| Enterprise Value/EBIT | 0.23 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 99.36M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 614 793 7500 | |||
| Address | 4995 Bradenton Avenue Dublin, OH 43017-3552 | |||
| Website | www.navidea.com | |||
| Country | United States | |||
| Year Founded | 1983 | |||
| Profitability | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,704,016.66% | |||
| Profit Margin | -197,066.66% | |||
| Management Effectiveness | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -106.88% | |||
| Return on Equity | -- | |||
| Income Statement | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 600.00 | |||
| Total Revenue (TTM) | 600.00 | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -49.40K | |||
| EBITDA (TTM) | -10.12M | |||
| EBIT (TTM) | -10.22M | |||
| Net Income (TTM) | -1.18M | |||
| Net Income Avl. to Common (TTM) | -1.18M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 60.49% | |||
| EPS Diluted (TTM) | -0.05 | |||
| EPS Diluted Growth (Q YOY) | 90.99% | |||
| Balance Sheet | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.86M | |||
| Cash Per Share (Q) | $0.04 | |||
| Total Current Assets (Q) | 4.50M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | -2.98M | |||
| Current Ratio (Q) | 0.564 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 5.70M | |||
| Total Current Liabilities (Q) | 7.98M | |||
| Total Debt (Q) | 1.26M | |||
| Total Liabilities (Q) | 8.68M | |||
| Total Common Equity (Q) | -3.27M | |||
| Cash Flow | NAVB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -176.40K | |||
| Cash from Financing (TTM) | 1.18M | |||
| Net Change in Cash (TTM) | 1.54M | |||
| Levered Free Cash Flow (TTM) | -6.86M | |||
| Cash from Operations (TTM) | 535.30K | |||
